BP
SMMT icon

BBR Partners’s Summit Therapeutics SMMT Stock Holding History

BBR Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$235K – 215
2020
Q4 		$235K Hold
50,000
– – 0.02% 169
2020
Q3 		$172K Hold
50,000
– – 0.01% 174
2020
Q2 		$149K Buy
+50,000
New +$172K 0.02% 158

Other funds holding SMMT

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BBR Partners's SMMT Position: Q1 2021 in Review

BBR Partners sold out of Summit Therapeutics (SMMT) in Q1 2021, closing a stake of 50,000 shares — an estimated $235K sold.

BBR Partners first reported a position in SMMT in Q2 2020 and held it in 3 quarters. The position peaked at $235K in Q4 2020. 41 funds tracked by Wall St. Rank hold SMMT as of Q1 2021.

  • BBR Partners reported no remaining Summit Therapeutics position as of Q1 2021 after selling out during the quarter.
  • BBR Partners sold 50,000 Summit Therapeutics shares in Q1 2021, an estimated $235K.
  • BBR Partners first reported a position in Summit Therapeutics in Q2 2020 and held it in 3 quarters.
  • BBR Partners's Summit Therapeutics position peaked at $235K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2021.

Based on BBR Partners's 13F filing for Q1 2021, filed 17 May 2021.